Systematic evaluation of butylphthalide soft capsule in the treatment of cognitive dysfunction in Parkinsons disease
-
摘要: 目的 对丁苯酞软胶囊治疗帕金森病认知功能障碍的有效性进行系统评价。 方法 检索国内外数据库中丁苯酞软胶囊治疗帕金森病认知功能障碍的随机对照研究,利用Revman 5.1进行Meta分析。 结果 共纳入9篇文献,755名受试者。从系统评价结果来看:与对照组相比,丁苯酞软胶囊能显著降低UPDRS评分[MD=-11.16,95%CI(-14.07~-8.25),P<0.001],能显著增加MoCA评分[MD=3.22,95%CI(2.39~4.05),P<0.001],能显著增加MMSE评分[MD=3.05,95%CI(2.24~3.87),P<0.001],能显著增加ADL评分[MD=13.05,95%CI(11.53~14.57),P<0.001];能显著降低CRP水平[MD=-2.69,95%CI(-2.69~-2.27),P<0.001],能显著升高NT-3水平[MD=8.48,95%CI(7.35~9.61),P<0.001],能显著降低PARK7水平[MD=-10.88,95%CI(-12.35~-9.40),P<0.001]。 结论 丁苯酞软胶囊能有效改善帕金森病认知功能障碍,效果显著。但本次研究存在一定的局限性,仍需设计更为良好的临床随机对照研究来验证。Abstract: Objective To systematically evaluate the efficacy of butylphthalide soft capsule in the treatment of cognitive impairment in Parkinson's disease. Methods Randomized controlled trials of butylphthalide soft capsules in the treatment of cognitive impairment in Parkinson's disease were retrieved from domestic and foreign databases. Revman 5.1 was used for meta-analysis. Results A total of 9 articles and 755 subjects were included. Compared with the control group, butylphthalide soft capsules could significantly reduce UPDRS score[MD=-11.16,95%CI(-14.07 to-8.25), P<0.001], and increase MoCA score[MD=3.22, 95% CI(2.39-4.05), P<0.001], MMSE score[MD=3.05, 95% CI(2.24-3.87), P<0.001], and ADL score[MD=13.05, 95% CI(11.53-14.57, P<0.001]. It could significantly reduce CRP level[MD=-2.69, 95% CI(-2.69 to-2.27), P<0.001] and PARK7 level[MD=-10.88, 95% CI(-12.35 to-9.40), P<0.001], and significantly increase NT-3 level[MD=8.48, 95% CI(7.35-9.61), P<0.001]. Conclusion Butylphthalide soft capsule can significantly improve the cognitive impairment of Parkinson's disease. However, there are some limitations in this study, which still need to be verified by a better clinical randomized controlled study.
-
Key words:
- Butylphthalide /
- Parkinson's disease /
- Cognitive impairment /
- Meta-analysis
点击查看大图
计量
- 文章访问数: 174
- HTML全文浏览量: 30
- PDF下载量: 1
- 被引次数: 0